Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Albireo Recognizes International Alagille Syndrome Awareness Day 2021
Albireo Pharma, Inc.January 22, 2021 GMT
BOSTON, Jan. 22, 2021 (GLOBE NEWSWIRE) Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today joins the Alagille community in commemorating the second annual International Alagille Syndrome Awareness Day on January 24, 2021 in honor of Dr. Daniel Alagille’s birthday. Alagille syndrome (ALGS) is a rare genetic disorder that can affect the liver, heart and other parts of the body. Albireo leaders reaffirm the Company’s commitment to advancing life-changing research and join the community in bringing greater awareness to patients and families affected by this rare and devastating disorder.